Prospera Financial Services Inc Raises Holdings in Boston Scientific Corporation $BSX

Prospera Financial Services Inc grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 17.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,251 shares of the medical equipment provider’s stock after buying an additional 1,348 shares during the period. Prospera Financial Services Inc’s holdings in Boston Scientific were worth $994,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Riverwater Partners LLC boosted its position in Boston Scientific by 3.3% during the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock worth $333,000 after purchasing an additional 98 shares during the period. IVC Wealth Advisors LLC boosted its holdings in Boston Scientific by 4.9% in the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock worth $236,000 after buying an additional 102 shares during the period. HHM Wealth Advisors LLC grew its stake in Boston Scientific by 13.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock valued at $89,000 after buying an additional 103 shares in the last quarter. Rise Advisors LLC grew its stake in Boston Scientific by 13.9% in the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock valued at $85,000 after buying an additional 103 shares in the last quarter. Finally, MQS Management LLC raised its holdings in Boston Scientific by 2.5% during the 2nd quarter. MQS Management LLC now owns 4,588 shares of the medical equipment provider’s stock valued at $493,000 after acquiring an additional 110 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 175,782 shares of company stock valued at $17,742,314. Insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Wells Fargo & Company lifted their price target on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Morgan Stanley increased their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Royal Bank Of Canada restated an “outperform” rating and issued a $125.00 price objective on shares of Boston Scientific in a research report on Monday, September 29th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $124.00 target price on shares of Boston Scientific in a report on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $123.77.

Boston Scientific Stock Up 1.6%

Shares of NYSE:BSX opened at $104.12 on Thursday. The stock has a market capitalization of $154.34 billion, a P/E ratio of 55.68, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The stock’s 50-day moving average price is $99.85 and its 200-day moving average price is $102.54. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the previous year, the company posted $0.63 EPS. Boston Scientific’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.